case_images: PMC3420641_01
case_images: Karyotype analysis showed t(9;11)(p22;q23). At the time of diagnosis, bone marrow cells were analyzed by commercially available service (BML laboratory, Japan). Twenty of the 20 metaphases cells disclosed t(9;11)(p22;q23) in G-banding method.
case_images: CRIM.HEMATOLOGY2011-273070.001.jpg
case_images: PMC3420641_01_CRIM.HEMATOLOGY2011-273070.001.jpg
case_images: fig1
case_images: Chromosome analysis of the patient's bone marrow using the G-band method determined that all of the extracted dividing cells had the t(9;11)(p22;q23) abnormality (Figure 1).
case_images: Clinical course. Disseminated intravascular coagulation, DIC, was diagnosed on February 5 in 2010 (the 1st hospital day, day 1), then 25,600 units of recombinant thrombomodulin alpha (Recomodulin) were administered for 6 days. Additional antithrombin III agent was also supplied on days 4 and 5. Several DIC markers rapidly improved on day 6, and bleeding tendency controlled effectively after Recomodulin administration. Adequate times of platelets transfusion (PC transfusion) were needed to overcome DIC or bone marrow suppression after chemotherapy. Patient achieved the 1st complete remission, CR on Mar. 11 in 2010 (day 35). Then, patient has completed 4 courses of consolidation chemotherapy, and the 1st CR has maintained until the present day.
case_images: CRIM.HEMATOLOGY2011-273070.002.jpg
case_images: PMC3420641_01_CRIM.HEMATOLOGY2011-273070.002.jpg
case_images: fig2
case_images: DIC was diagnosed on the first hospital day (Feb 5th 2010; DAY 1), and 25,600 units of recombinant thrombomodulin alpha (Recomodulin) were administered for 6 days (Figure 2).